Category: Federal Forum Posters
Purpose: To compare the composite rate of all-cause mortality and heart failure exacerbations in subjects receiving sacubitril/valsartan at maintenance doses of 24/46 mg and 49/51 mg compared to subjects maintained on the target dose of 97/103 mg in a veteran population.
Methods: This retrospective chart review will include medical records of subjects between 18-89 years of age with an established diagnosis of heart failure with reduced ejection fraction (HFrEF) and received at least one outpatient prescription for sacubitril/valsartan. Baseline demographic information will be recorded (i.e. gender, age, race, sacubitril/valsartan dose, ejection fraction, other heart failure medications, comorbid disease states) as well as data reflecting renal function, serum potassium, blood pressure, and occurrence of heart failure exacerbation or death. The primary outcome will be to compare the composite rate of all-cause mortality and heart failure exacerbations in subjects receiving sacubitril/valsartan at maintenance doses of 24/46 mg and 49/51 mg compared to subjects maintained on the target dose of 97/103 mg. Secondary outcomes will include all-cause mortality, rate of heart failure exacerbations, change in left ventricular ejection fraction confirmed by ECHO, rates of discontinuation, comparison outcomes of patients followed by pharmacist-run clinic to those followed elsewhere, renal function decline, and ADRs of the medication at all doses. The primary outcome will be analyzed using Chi-Square analysis whereas and baseline characteristics and secondary outcomes will be assessed using Chi-Square analysis for all categorical data and Student’s T-test for all continuous data.
Results: not applicable
Conclusion: not applicable
Steven Menachof– PGY1 Pharmacy Resident, Southern Arizona VA Health Care System, Tucson, AZ